Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADR012
MIFTS: 50

Adrenal Gland Disease

Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Adrenal Gland Disease

About this section

MalaCards integrated aliases for Adrenal Gland Disease:

Name: Adrenal Gland Disease 12 15 17
Adrenal Gland Diseases 45 74
Adrenal Gland Disorders 44

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:9553
ICD9CM 36 255 255.9
MeSH 45 D000307
NCIt 51 C26690
SNOMED-CT 69 30171000
ICD10 34 E27 E27.8 E27.9
UMLS 74 C0001621
Sources

Summaries for Adrenal Gland Disease

About this section
MedlinePlus : 44 The adrenal glands are small glands located on top of each kidney. They produce hormones that you can't live without, including sex hormones and cortisol. Cortisol helps you respond to stress and has many other important functions. With adrenal gland disorders, your glands make too much or not enough hormones. In Cushing's syndrome, there's too much cortisol, while with Addison's disease, there is too little. Some people are born unable to make enough cortisol. Causes of adrenal gland disorders include Genetic mutations Tumors including pheochromocytomas Infections A problem in another gland, such as the pituitary, which helps to regulate the adrenal gland Certain medicinesTreatment depends on which problem you have. Surgery or medicines can treat many adrenal gland disorders. NIH: National Institute of Child Health and Human Development

MalaCards based summary : Adrenal Gland Disease, also known as adrenal gland diseases, is related to adrenal insufficiency, congenital, with 46,xy sex reversal, partial or complete and corticosteroid-binding globulin deficiency. An important gene associated with Adrenal Gland Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and Aldosterone synthesis and secretion. The drugs Hydrocortisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, pituitary and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 An endocrine system disease that is located in the adrenal gland.

Wikipedia : 77 Adrenal gland disorders (or diseases) are conditions that interfere with the normal functioning of the... more...

Sources

Related Diseases for Adrenal Gland Disease

About this section

Diseases related to Adrenal Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Related Disease Score Top Affiliating Genes
1 adrenal insufficiency, congenital, with 46,xy sex reversal, partial or complete 31.2 CYP11A1 CYP17A1 POMC
2 corticosteroid-binding globulin deficiency 11.1
3 waterhouse-friderichsen syndrome 11.1
4 allergic encephalomyelitis 10.4 CRH POMC
5 inappropriate adh syndrome 10.4 POMC REN
6 gangliocytoma 10.4 CRH POMC
7 bronchus adenoma 10.4 POMC SST
8 bronchial adenomas/carcinoids childhood 10.4 POMC SST
9 ovarian serous adenofibroma 10.4 NR3C1 POMC
10 acidophil adenoma 10.4 POMC SST
11 hypoaldosteronism 10.4 CYP11B2 POMC REN
12 arthrogryposis, distal, type 3 10.4 NR3C2 REN
13 allergic urticaria 10.3 CRH NR3C1
14 familial glucocorticoid deficiency 10.3 NR0B1 POMC REN
15 pseudohypoaldosteronism, type i, autosomal dominant 10.3 NR3C2 REN
16 familial hyperaldosteronism 10.3 CYP11B1 CYP11B2 KCNJ5
17 acth deficiency, isolated 10.3 CRH POMC
18 familial hypertension 10.3 CYP11B2 NR3C2 REN
19 pseudohyperkalemia, familial, 2, due to red cell leak 10.3 CYP11B2 NR3C2 REN
20 hormone producing pituitary cancer 10.3 PRKAR1A SST
21 mental depression 10.3 CRH NR3C1 POMC
22 ectopic cushing syndrome 10.3 CRH POMC SST
23 pancreatic endocrine carcinoma 10.3 POMC SST
24 chronic fatigue syndrome 10.3 CRH NR3C1 POMC
25 apparent mineralocorticoid excess 10.3 NR3C1 NR3C2 REN
26 glucose metabolism disease 10.2 POMC REN SST
27 adenohypophysitis 10.2 POMC PRL
28 mood disorder 10.2 CRH NR3C1 POMC
29 pituitary apoplexy 10.2 POMC PRL
30 cytochrome p450 oxidoreductase deficiency 10.2 CYP17A1 POMC
31 hypothalamic disease 10.2 CRH POMC PRL
32 sheehan syndrome 10.2 CRH POMC PRL
33 male reproductive organ benign neoplasm 10.2 POMC PRKAR1A
34 hypothyroidism, congenital, nongoitrous, 4 10.2 CRH POMC PRL
35 hypoadrenalism 10.2 CRH POMC
36 sella turcica neoplasm 10.2 POMC PRL
37 hypokalemia 10.1 NR3C1 NR3C2 POMC REN
38 amenorrhea 10.1 CRH POMC PRL
39 hypopituitarism 10.1 CRH POMC PRL
40 tuberculum sellae meningioma 10.1 POMC PRL
41 liddle syndrome 1 10.1 CYP11B2 NR3C1 NR3C2 REN
42 primary pigmented nodular adrenocortical disease 10.1 PDE11A POMC PRKAR1A
43 pituitary infarct 10.1 POMC PRL SST
44 chiasmal syndrome 10.1 POMC PRL SST
45 hyperpituitarism 10.1 POMC PRL SST
46 pheochromocytoma 10.1 CRH POMC REN SST
47 tsh producing pituitary tumor 10.1 POMC PRL SST
48 functioning pituitary adenoma 10.1 POMC PRL SST
49 prolactin producing pituitary tumor 10.1 PRL SST
50 melancholia 10.1 CRH PRL

Comorbidity relations with Adrenal Gland Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypertension, Essential

Graphical network of the top 20 diseases related to Adrenal Gland Disease:



Diseases related to Adrenal Gland Disease
Sources

Symptoms & Phenotypes for Adrenal Gland Disease

About this section

GenomeRNAi Phenotypes related to Adrenal Gland Disease according to GeneCards Suite gene sharing:

27 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.93 ATP1A4 CYP17A1 NR3C1 PDE11A
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 9.93 NR3C1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 9.93 PDE11A
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.93 ATP1A4
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-15 9.93 ATP1A4
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.93 CYP17A1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 9.93 ATP1A4
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.93 ATP1A4
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.93 NR3C1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.93 CYP17A1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 9.93 PDE11A
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 9.93 ATP1A4 PDE11A
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.93 CYP17A1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.93 CYP17A1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-98 9.93 NR3C1
16 Reduced mammosphere formation GR00396-S 9.23 ATP1A1 ATP1A4 CYP11B1 KCNJ5 NR0B1 NR3C1

MGI Mouse Phenotypes related to Adrenal Gland Disease:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 ATP1A1 CACNA1D CRH CYP11A1 CYP11B1 CYP17A1
2 homeostasis/metabolism MP:0005376 10.33 ARMC5 ATP1A1 ATP1A4 CACNA1D CRH CYP11A1
3 growth/size/body region MP:0005378 10.28 ARMC5 ATP1A4 CACNA1D CRH CYP11A1 CYP11B1
4 cardiovascular system MP:0005385 10.24 ATP1A1 CACNA1D CYP11A1 CYP11B1 CYP11B2 KCNJ5
5 endocrine/exocrine gland MP:0005379 10.2 ARMC5 CACNA1D CRH CYP11A1 CYP11B1 CYP11B2
6 cellular MP:0005384 10.18 ATP1A4 CACNA1D CRH CYP11A1 CYP11B1 CYP17A1
7 mortality/aging MP:0010768 10.1 ARMC5 ATP1A1 CACNA1D CYP11A1 CYP11B1 CYP17A1
8 adipose tissue MP:0005375 10 CRH CYP11B2 CYP17A1 NR3C1 POMC PRKAR1A
9 liver/biliary system MP:0005370 9.91 CRH CYP11A1 CYP11B2 NR3C1 POMC PRKAR1A
10 nervous system MP:0003631 9.9 CACNA1D CRH CYP11A1 CYP11B2 NR3C1 NR3C2
11 muscle MP:0005369 9.8 ATP1A1 CYP11A1 CYP11B1 NR3C1 NR3C2 PRKAR1A
12 renal/urinary system MP:0005367 9.5 CRH CYP11B1 CYP11B2 NR3C1 NR3C2 POMC
13 reproductive system MP:0005389 9.28 ATP1A4 CYP11A1 CYP11B2 CYP17A1 NR0B1 NR3C1
Sources

Drugs & Therapeutics for Adrenal Gland Disease

About this section

Drugs for Adrenal Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 384)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-23-7 5754
2
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-03-3
3
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
4
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
5
Eplerenone Approved Phase 4,Not Applicable 107724-20-9 443872 150310
6
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
7
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
8
Captopril Approved Phase 4 62571-86-2 44093
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
10
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
12
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
14
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
16
Mifepristone Approved, Investigational Phase 4,Phase 3,Phase 2 84371-65-3 55245
17
Cosyntropin Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 16960-16-0 16129617
18
Losartan Approved Phase 4 114798-26-4 3961
19
Angiotensin II Approved, Investigational Phase 4,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
20
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
21
Fludrocortisone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 127-31-1 31378
22
Cortisone Experimental Phase 4,Phase 2,Not Applicable 53-06-5 222786
23
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2 2920-86-7
24 Hydrocortisone hemisuccinate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Hydrocortisone-17-butyrate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Epinephryl borate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Mydriatics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Sympathomimetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Natriuretic Agents Phase 4,Not Applicable
43 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Antihypertensive Agents Phase 4,Phase 3,Not Applicable
45 Diuretics, Potassium Sparing Phase 4,Not Applicable
46 diuretics Phase 4,Not Applicable
47 Mineralocorticoid Receptor Antagonists Phase 4,Phase 3,Not Applicable
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Mineralocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
50 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 396)
# Name Status NCT ID Phase Drugs
1 Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism Unknown status NCT02282150 Phase 4 Hydrocortisone;Plenadren
2 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
3 Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? Unknown status NCT00553722 Phase 4 Eplerenone;Placebo
4 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
5 Effect of Treatment With Stress-Doses Glucocorticoid in Patients With Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT00773058 Phase 4 hydrocortisone;placebo
6 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism Completed NCT01990560 Phase 4 Mifepristone
7 Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT) Completed NCT01546922 Phase 4 Hydrocortisone
8 Revival of Stem Cells in Addison's Study Completed NCT01371526 Phase 4 depot tetracosactide
9 Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism Completed NCT00155064 Phase 4 captopril, Losartan (drug)
10 Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment Completed NCT00975078 Phase 4 prednisone
11 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Completed NCT00851942 Phase 4 Synacthen (Tetracosactrin)
12 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
13 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
14 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
15 Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment Recruiting NCT03760835 Phase 4 Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone);Dual release hydrocortisone (plenadren)
16 Optimising Steroid Replacement in Patients With Adrenal Insufficiency Enrolling by invitation NCT03282487 Phase 4 Modified release hydrocortisone
17 A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT) Not yet recruiting NCT03210545 Phase 4 Dexamethasone
18 Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency Terminated NCT01089075 Phase 4 Hydrocortisone;Placebo
19 Adrenal Insufficiency in Septic Shock Terminated NCT00842933 Phase 4 Corticosteroid;Corticosteroid
20 Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal Volunteers Withdrawn NCT03752190 Phase 4 Cosyntropin
21 The Effect of Dexamethasone on Cortisol Levels in Patients Undergoing Thyroid Surgery Withdrawn NCT01045876 Phase 4 Dexamethasone
22 Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis Withdrawn NCT00368381 Phase 4 Hydrocortisone
23 COrticosteroid in Congenital Adrenal Hyperplasia Unknown status NCT02552251 Phase 2, Phase 3
24 Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening Completed NCT00037843 Phase 3 I-131 Iodocholesterol
25 Extension Study for Patients Entered Into Study Infacort 003 Completed NCT02733367 Phase 3 Infacort®
26 Treatment of Adrenal Insufficiency in Children Completed NCT02720952 Phase 3 Infacort®
27 Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency Completed NCT00915343 Phase 2, Phase 3 hydrocortisone (modified release), oral tablet 20 and 5 mg;Hydrocortisone, oral tablet, 10 mg
28 Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency Completed NCT00575341 Phase 3 Dehydroepiandrosterone;placebo
29 SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan. Completed NCT01096654 Phase 3
30 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency Completed NCT00004313 Phase 3 dehydroepiandrosterone
31 Glucocorticoid Treatment in Addison's Disease Completed NCT01063569 Phase 2, Phase 3 Solu-Cortef (hydrocortisone);Cortef (hydrocortisone)
32 Treatment for Endogenous Cushing's Syndrome Completed NCT01838551 Phase 3 COR-003
33 Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation Completed NCT00997594 Phase 2, Phase 3
34 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
35 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
36 The Role of Mineralocorticoid Receptors in Vascular Function Completed NCT00759525 Phase 2, Phase 3 Glycyrrhetic Acid;Placebo
37 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
38 MD1003-AMN MD1003 in Adrenomyeloneuropathy Completed NCT02961803 Phase 2, Phase 3 MD1003 100 mg capsule;Placebo
39 Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia Completed NCT02716818 Phase 3 Chronocort®;standard glucocorticoid therapy
40 Prevention of Metabolic Complications of Glucocorticoid Excess Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
41 Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury Completed NCT01093261 Phase 3 Placebo;Hydrocortisone Fludrocortisone
42 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
43 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
44 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
45 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
46 Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Completed NCT00007020 Phase 3 Cholic Acids
47 A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Recruiting NCT03697109 Phase 3 Relacorilant
48 Adrenal Artery Ablation for Primary Aldosteronism Recruiting NCT03653845 Phase 3 Sequenced antihypertensvie drugs with titrated dosage
49 Adrenal Artery Ablation Treats Primary Aldosteronism Recruiting NCT03398785 Phase 3
50 A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome. Recruiting NCT03277690 Phase 3 Levoketoconazole;Placebo

Search NIH Clinical Center for Adrenal Gland Disease

Cochrane evidence based reviews: adrenal gland diseases

Sources

Genetic Tests for Adrenal Gland Disease

About this section
Sources

Anatomical Context for Adrenal Gland Disease

About this section

MalaCards organs/tissues related to Adrenal Gland Disease:

42
Adrenal Gland, Pituitary, Testes, Kidney, Lung, Bone, Thyroid

The Foundational Model of Anatomy Ontology organs/tissues related to Adrenal Gland Disease:

20
The Adrenal Gl
Sources

Publications for Adrenal Gland Disease

About this section

Articles related to Adrenal Gland Disease:

# Title Authors Year
1
Lateral Transperitoneal Adrenalectomy Versus Posterior Retroperitoneoscopic Adrenalectomy for Benign Adrenal Gland Disease: Randomized Controlled Trial at a Single Tertiary Medical Center. ( 29189215 )
2017
2
Serum inhibin concentration in dogs with adrenal gland disease and in healthy dogs. ( 23311716 )
2013
3
Adrenal gland disease in ferrets. ( 18165141 )
2008
4
Adrenal gland disease in ferrets. ( 9076915 )
1997
Sources

Variations for Adrenal Gland Disease

About this section
Sources

Expression for Adrenal Gland Disease

About this section
Search GEO for disease gene expression data for Adrenal Gland Disease.
Sources

Pathways for Adrenal Gland Disease

About this section

Pathways related to Adrenal Gland Disease according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Myometrial Relaxation and Contraction Pathways 1
Show member pathways
 12.26 ATP1A4 CACNA1D CRH KCNJ5 PRKAR1A
2
Aldosterone synthesis and secretion 38
Show member pathways
 12.19 ATP1A1 ATP1A4 CACNA1D CYP11A1 CYP11B1 CYP11B2
3
Hepatic ABC Transporters 65
Show member pathways
 11.81 ATP1A1 ATP1A4 CACNA1D
4
Nuclear Receptor transcription pathway 67
Show member pathways
 11.65 NR0B1 NR3C1 NR3C2
5
Glucocorticoid receptor regulatory network 1
11.6 NR3C1 POMC PRL
6
Corticotropin-releasing hormone signaling pathway 1
11.59 CRH CYP11A1 CYP11B1 POMC
7
Cardiac muscle contraction 38
11.56 ATP1A1 ATP1A4 CACNA1D
8
Antiarrhythmic Pathway, Pharmacodynamics 62
11.38 ATP1A1 CACNA1D KCNJ5
9
Metabolism of steroid hormones 67
Show member pathways
 11.3 CYP11A1 CYP11B1 CYP11B2 CYP17A1 POMC
10
Steroid hormone biosynthesis 38
Show member pathways
 11.28 CYP11A1 CYP11B1 CYP11B2 CYP17A1
11
Carbohydrate digestion and absorption 38
11.25 ATP1A1 ATP1A4 CACNA1D
12
Aldosterone-regulated sodium reabsorption 38
11.15 ATP1A1 ATP1A4 NR3C2
13
superpathway of steroid hormone biosynthesis 1
Show member pathways
 10.78 CYP11B1 CYP11B2 CYP17A1
14
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 62
10.32 CRH POMC
Sources

GO Terms for Adrenal Gland Disease

About this section

Cellular components related to Adrenal Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase complex GO:0005890 8.62 ATP1A1 ATP1A4

Biological processes related to Adrenal Gland Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.8 ATP1A1 CRH REN SST
2 cholesterol metabolic process GO:0008203 9.74 CYP11A1 CYP11B1 CYP11B2
3 potassium ion import across plasma membrane GO:1990573 9.69 ATP1A1 ATP1A4 KCNJ5
4 regulation of blood pressure GO:0008217 9.67 ATP1A1 CYP11B1 POMC REN
5 steroid metabolic process GO:0008202 9.65 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1
6 cellular sodium ion homeostasis GO:0006883 9.62 ATP1A1 ATP1A4
7 cardiac muscle cell action potential involved in contraction GO:0086002 9.61 ATP1A1 CACNA1D
8 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.61 ATP1A1 ATP1A4
9 response to immobilization stress GO:0035902 9.61 CRH NR0B1 REN
10 cellular potassium ion homeostasis GO:0030007 9.6 ATP1A1 ATP1A4
11 cellular response to steroid hormone stimulus GO:0071383 9.59 ATP1A1 NR3C1
12 hypothalamus development GO:0021854 9.58 CRH NR0B1
13 sodium ion export across plasma membrane GO:0036376 9.58 ATP1A1 ATP1A4
14 cellular response to peptide hormone stimulus GO:0071375 9.58 CYP11A1 CYP11B1 CYP11B2
15 cellular response to potassium ion GO:0035865 9.55 CYP11B1 CYP11B2
16 hormone-mediated apoptotic signaling pathway GO:0008628 9.54 CRH SST
17 cellular response to hormone stimulus GO:0032870 9.52 CYP11B1 CYP11B2
18 C21-steroid hormone biosynthetic process GO:0006700 9.5 CYP11A1 CYP11B1 CYP11B2
19 aldosterone biosynthetic process GO:0032342 9.48 CYP11B1 CYP11B2
20 cortisol biosynthetic process GO:0034651 9.46 CYP11B1 CYP11B2
21 steroid biosynthetic process GO:0006694 9.35 CYP11A1 CYP11B1 CYP11B2 CYP17A1 NR0B1
22 sterol metabolic process GO:0016125 9.33 CYP11A1 CYP11B1 CYP11B2
23 parturition GO:0007567 9.26 CRH
24 glucocorticoid biosynthetic process GO:0006704 9.02 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1

Molecular functions related to Adrenal Gland Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.67 CYP11A1 CYP11B1 CYP11B2 CYP17A1
2 iron ion binding GO:0005506 9.62 CYP11A1 CYP11B1 CYP11B2 CYP17A1
3 steroid hormone receptor activity GO:0003707 9.58 NR0B1 NR3C1 NR3C2
4 hormone activity GO:0005179 9.56 CRH POMC PRL SST
5 ankyrin binding GO:0030506 9.51 ATP1A1 CACNA1D
6 3',5'-cyclic-GMP phosphodiesterase activity GO:0047555 9.48 PDE11A PRKAR1A
7 sodium:potassium-exchanging ATPase activity GO:0005391 9.46 ATP1A1 ATP1A4
8 steroid hormone binding GO:1990239 9.43 ATP1A1 NR3C1
9 corticosterone 18-monooxygenase activity GO:0047783 9.16 CYP11B1 CYP11B2
10 steroid 11-beta-monooxygenase activity GO:0004507 8.96 CYP11B1 CYP11B2
11 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 8.92 CYP11A1 CYP11B1 CYP11B2 CYP17A1
12 metal ion binding GO:0046872 10.19 ATP1A1 ATP1A4 CACNA1D CYP11A1 CYP11B1 CYP11B2
Sources

Sources for Adrenal Gland Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....